Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
在市場動盪和不確定時期，許多投資者轉向產生股息的股票。這些公司通常擁有很高的自由現金流，並通過獎勵股東來獎勵股東 高額股息支付。
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy .
Benzinga的讀者可以通過訪問我們的分析師股票評級頁面來查看分析師對他們最喜歡的股票的最新看法。交易者可以對Benzinga龐大的分析師評級數據庫進行排序，包括 根據分析師的準確性 。
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
以下是最準確的分析師對醫療保健行業三隻高收益股票的評級。
Pfizer Inc. (NYSE:PFE)
輝瑞公司（紐約證券交易所代碼：PFE）
- Dividend Yield: 6.38%
- Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating with a price target of $45 on April 5, 2024. This analyst has an accuracy rate of 64%.
- Guggenheim analyst Vamil Divan initiated coverage on the stock with a Buy rating and a price target of $36 on Feb. 23, 2024. This analyst has an accuracy rate of 77%.
- Recent News: Pfizer recently released top-line immunogenicity and safety data from the ongoing pivotal Phase 3 MONeT trial,evaluating a single dose of Abrysvo versus placebo in adults 18 to 59 years of age at risk of developing severe respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD).
- 股息收益率：6.38%
- 坎託·菲茨傑拉德分析師路易絲·陳在2024年4月5日重申增持評級，目標股價爲45美元。這位分析師的準確率爲64％。
- 古根海姆分析師瓦米爾·迪萬於2024年2月23日開始對該股進行報道，評級爲買入，目標股價爲36美元。這位分析師的準確率爲77％。
- 最新消息：輝瑞最近發佈了正在進行的關鍵性3期MoNet試驗的主要免疫原性和安全性數據，該試驗評估了18至59歲有患嚴重呼吸道合胞病毒（RSV）相關下呼吸道疾病（LRTD）風險的成年人單劑量的Abrysvo對比安慰劑。
GSK plc (NYSE:GSK)
葛蘭素史克公司（紐約證券交易所代碼：GSK）
- Dividend Yield: 3.61%
- BMO Capital analyst Etzer Darout maintained an Outperform rating and cut the price target from $82 to $80 on Feb. 12, 2024. This analyst has an accuracy rate of 60%.
- Morgan Stanley analyst Mark Purcell initiated coverage on the stock with an Overweight rating and a price target of $85 on Jan. 23, 2024. This analyst has an accuracy rate of 65%.
- Recent News: CureVac released interim data on Thursday, April 4, from studies it conducted on its seasonal influenza vaccine candidate. The study is part of a collaboration with GSK Plc.
- 股息收益率：3.61%
- BMO Capital分析師埃策·達魯特維持跑贏大盤的評級，並於2024年2月12日將目標股價從82美元下調至80美元。這位分析師的準確率爲60％。
- 摩根士丹利分析師馬克·珀塞爾於2024年1月23日開始對該股進行報道，增持評級，目標股價爲85美元。該分析師的準確率爲65％。
- 最新消息：CureVac於4月4日星期四發佈了針對其季節性流感候選疫苗的研究的中期數據。該研究是與葛蘭素史克集團合作的一部分。
Patterson Companies, Inc. (NASDAQ:PDCO)
帕特森公司有限公司（納斯達克股票代碼：PDCO）
- Dividend Yield: 4.05%
- Morgan Stanley analyst Erin Wright maintained an Equal-Weight rating and slashed the price target from $38 to $35 on Nov. 30, 2023. This analyst has an accuracy rate of 78%.
- Stifel analyst Jonathan Block reiterated a Hold rating with a price target of $32 on Nov. 28, 2023. This analyst has an accuracy rate of 79%.
- Recent News: On March 11, Patterson Companies approved a $500 million stock buyback and declared a quarterly dividend of 26 cents per share.
- 股息收益率：4.05%
- 摩根士丹利分析師艾琳·賴特維持同等權重評級，並於2023年11月30日將目標股價從38美元下調至35美元。該分析師的準確率爲78％。
- Stifel分析師喬納森·布洛克在2023年11月28日重申了持有評級，目標股價爲32美元。這位分析師的準確率爲79％。
- 最新消息：3月11日，帕特森公司批准了5億美元的股票回購，並宣佈季度股息爲每股26美分。
Read More: Jim Cramer Says WESCO International Is A Buy, Recommends Buying This Stock Under $20
閱讀更多： 吉姆·克萊默說WESCO International值得買入，建議在20美元以下買入這隻股票
譯文內容由第三人軟體翻譯。